Orasis Pharmaceuticals
orasis-pharma.com
Actively hiring
Prescription Drugs
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$108M
2 rounds on record
Latest round
$78M
Series D · Oct 2024 · 2 yr ago
Team
201-500
employees, estimated range
Backers
1
Arboretum Ventures
The money's age
Due for its next round
24 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 10, 2024
Raised a round Series D $78M · Pulse 2.0
Oct 4, 2021
New executive Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan · streetinsider.com
Sep 11, 2020
Raised a round Venture round $30M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series D | Oct 2024 | $78M | — | Pulse 2.0 |
| Venture round | Sep 2020 | $30M | — | fiercebiotech.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Arboretum Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Transforming Eye Care With Precision Medicine. Age-related macular degeneration (AMD) impacts one in eight people over the age of fifty and…
Discover how innovative eye treatments from Tenpoint Therapeutics™ may help restore lens clarity and rejuvenate vision in aging eyes.
VitalStream® is an FDA-approved and clinically-validated wireless, ICU-grade noninvasive hemodynamic and blood pressure monitor. Schedule a…
Azurity Pharmaceuticals is a privately held specialty pharmaceutical company that develops and markets medicines for patients underserved…
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.
News
FDA Clears Orasis Pharmaceuticals' Presbyopia Treatment PharmExec
Qlosi indicated for adult patients.
Read more
Report
ORASIS PHARMACEUTICALS DOUBLES DOWN ON EYE CARE PROFESSIONALS, NOT TELEHEALTH, AS QLOSI REFILLS REACH 49%¹
/PRNewswire/ -- Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, announced two new offerings...
Read more
Report
ORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIA
/PRNewswire/ -- Orasis Pharmaceuticals and Aspen Australia announced that Aspen has submitted a New Drug Application in Australia to the Therapeutic Goods...
Read more
Report
Orasis Pharmaceuticals: $78 Million (Series D) Raised To Support Launch Of Qlosi
Orasis Pharmaceuticals, a ophthalmic pharmaceutical company focused on reshaping vision possibilities, announced a $78 million Series D round to support the commercial launch of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel correctiv
Read more
Report
Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan
HERZLIYA, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the appointment
Read more
Report
Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan
Read more
Report
Presbyopia and Your Eyes
Presybyopia: What is presbyopia? The natural decline in vision that often comes with age. Know its causes and solutions.
Read more
Report